Author

D. Duveau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Thomas· 3 shared A. Gondane· 1 shared C. Farrell· 1 shared D. Roberts· 1 shared G. Q. Fei· 1 shared H. M. Itkonen· 1 shared J. Amason· 1 shared J. Inglese· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Thomas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Compromised CDK12 activity causes dependency on the non-essential spliceosome components

S. Pallasaho, A. Gondane, D. Duveau, C. Thomas, M. Loda, H. M. Itkonen

This study shows that compromised CDK12 activity in prostate cancer cells leads to addiction to non-essential spliceosome components and lower DNA methylation, suggesting potential therapeutic targets.

bioRxiv · Dec 7, 2021 · PreprintCancer Biology

O-GlcNAc regulates gene expression by controlling detained intron splicing

Z.-W. Tan, G. Q. Fei, J. Paulo, S. Bellaousov, S. E. S. Martin, D. Duveau, C. Thomas, S. Gygi, P. Boutz, S. Walker

This study shows O-GlcNAc modification regulates detained intron splicing, affecting gene expression and linking nutrient conditions to transcriptional regulation.

bioRxiv · Mar 27, 2020Cell Biology

A Homogeneous SIRPα-CD47 Cell-Based, Ligand-Binding Assay: Utility for Small Molecule Drug Development in Immuno-oncology.

T. Burgess, J. Amason, J. Rubin, D. Duveau, L. Lamy, D. Roberts, C. Farrell, J. Inglese, C. Thomas, T. W. Miller

This paper develops a cell-based ligand-binding assay to identify small molecule inhibitors of the SIRP-CD47 interaction for immuno-oncology drug development.

bioRxiv · Dec 5, 2019Immunology